Stefano Pileri
Has grant
Direttore della Ematopatologia
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
MOLECULAR BASES OF DISEASE DISSEMINATION IN LYMPHOID MALIGNANCIES TO OPTIMIZE CURATIVE THERAPEUTIC STRATEGIES
Open Date: 2018-07-01
Close Date: 2025-06-01
Articles (12)
Purpose: A risk-adapted treatment strategy, the ISG/OS-2 trial, evaluated the use of mifamurtide in patients with P-glycoprotein (Pgp)–positive localized osteosarcoma. The primary objective was the identification of prognostic classifiers based on tumor microenvironment (TME) gene profiling in all patients and in those undergoing mifamurtide treatment. Experimental Design: RNA from pretreatment formalin-fixed, paraffin-embedded nondecalcified tissues of 62 patients was analyzed with the PanCancer Immune Profiling Panel (NanoString Technologies). Thirty-three (53%) of 62 Pgp-positive patients underwent chemotherapy + mifamurtide; 29 (47%) of 62 Pgp-negative patients received chemotherapy alone. Univariate Cox regression, ROC curve, and CIBERSORTx algorithm gene deconvolution analyses were performed. Results: A 21-gene signature able to stratify all patients into high risk (Hi-R) and low risk (Lo-R) was identified: 5-year overall survival (OS) of 47% for Hi-R and 92% for Lo-R (P = 3e−06). TME of Lo-R compared with Hi-R was significantly enriched in CD8 T cells, regulatory T cells, and NK-activated cells and diminished in CD4 T cells. The 21-gene signature was validated in two independent sets: TARGET-OS The Cancer Genome Atlas (n = 62) and GSE33382 (n = 57). For patients treated with chemotherapy + mifamurtide, 31 mifamurtide-related genes able to distinguish Hi-R and Lo-R in terms of OS (P = 1e−09) and event-free survival (P = 3e−06) were also identified. After multivariate analysis, the 21- and 31-gene mifamurtide-related signatures were independently associated with OS (P = 0.00044 and P = 0.000079, respectively). Conclusions: A validated osteosarcoma TME prognostic gene signature has been identified, regardless of mifamurtide treatment. Importantly, a mifamurtide-related signature was also developed. Tumor–immune interactions possibly implicated in disease progression and treatment response were shown.
Year:
2025
Supplementary Figure S6: Venn diagram showing the 5 genes which are shared between the 21-gene signatureidentified in 62 primary osteosarcomas (discovery set) and the 31-gene signature related to the 33 osteosarcoma patients who underwent mifamurtide treatment
Year:
2025
Cox regression output , 31 genes selected based on LogRank≤0.05 significantly associated with overall survival (OS) in 33 localized primary high-grade osteosarcoma underwent chemotherapy (CT) combined with mifamurtide treatment
Year:
2025
Purpose: A risk-adapted treatment strategy, the ISG/OS-2 trial, evaluated the use of mifamurtide in patients with P-glycoprotein (Pgp)–positive localized osteosarcoma. The primary objective was the identification of prognostic classifiers based on tumor microenvironment (TME) gene profiling in all patients and in those undergoing mifamurtide treatment. Experimental Design: RNA from pretreatment formalin-fixed, paraffin-embedded nondecalcified tissues of 62 patients was analyzed with the PanCancer Immune Profiling Panel (NanoString Technologies). Thirty-three (53%) of 62 Pgp-positive patients underwent chemotherapy + mifamurtide; 29 (47%) of 62 Pgp-negative patients received chemotherapy alone. Univariate Cox regression, ROC curve, and CIBERSORTx algorithm gene deconvolution analyses were performed. Results: A 21-gene signature able to stratify all patients into high risk (Hi-R) and low risk (Lo-R) was identified: 5-year overall survival (OS) of 47% for Hi-R and 92% for Lo-R ( P = 3e−06). TME of Lo-R compared with Hi-R was significantly enriched in CD8 T cells, regulatory T cells, and NK-activated cells and diminished in CD4 T cells. The 21-gene signature was validated in two independent sets: TARGET-OS The Cancer Genome Atlas ( n = 62) and GSE33382 ( n = 57). For patients treated with chemotherapy + mifamurtide, 31 mifamurtide-related genes able to distinguish Hi-R and Lo-R in terms of OS ( P = 1e−09) and event-free survival ( P = 3e−06) were also identified. After multivariate analysis, the 21- and 31-gene mifamurtide-related signatures were independently associated with OS ( P = 0.00044 and P = 0.000079, respectively). Conclusions: A validated osteosarcoma TME prognostic gene signature has been identified, regardless of mifamurtide treatment. Importantly, a mifamurtide-related signature was also developed. Tumor–immune interactions possibly implicated in disease progression and treatment response were shown.
Year:
2025
Supplementary Figure S2:Overall survival of 62 patients with localized osteosarcoma (A) after a median follow-up of 107.8 months (IQR:92.5–128.4). (B) Overall survival for the 62 patients considered in the present study stratified as Pgp-positive and Pgp-negative (p = 0.6990).
Year:
2025
Background: Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization. Methods: Here, we report two cases of RS achieving long-term complete remission with intensified chemoimmunotherapy (Rituximab-G-MALL B-ALL/NHL2002 regimen) plus venetoclax induction, followed by haploidentical hematopoietic stem cell transplant (allo-HSCT). Venetoclax was given continuously for 14 consecutive days after every Rituximab-G-MALL cycle in off-label use. An accelerated venetoclax rump-up schedule was used in both patients to reach the maximal dose. Maximal venetoclax dose was 300 mg and 400 mg in patient 1 and patient 2, respectively. Results: The combined treatment was well tolerated, with no major infective complications or non-hematological toxicities. In both patients, immunosuppression was discontinued within day 180 after transplant with no graft-versus-host-disease flares. Both patients are alive and in continuous complete remission after 60 and 72 months following allo-HSCT. Conclusions: This report supports the feasibility of a combination treatment with BCL-2 inhibitors and intensive chemoimmunotherapy as a bridge to allo-HSCT in RS.
Year:
2024
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (27)
Stefan Barta
Academic Clinician Associate Professor
University of Pennsylvania
Emanuela Palmerini
Professor of Medicine
University of Toronto
ALESSANDRO FRANCHI
Professor of pathology
University of Pisa
alberto righi
IRCCS Istituto Ortopedico Rizzoli
Daniel J. Powell
Associate Professor
University of Pennsylvania
DAVIDE MARIA DONATI
Istituto Ortopedico Rizzoli
Thomas Tousseyn
Professor Dr. at KU Leuven
KU Leuven
Gerald Linette
Professor
University of Pennsylvania
Mohamed Abdel-Mohsen
Associate Professor
Northwestern University
Claudio Agostinelli
Associate Professor of Pathology
University of Bologna
cristina meazza
Fondazione IRCCS Istituto Nazionale dei Tumori
Giovanna Motta
Istituto Europeo di Oncologia
Stefan Dojcinov
Professor / Consultant Pathologist
Swansea Bay University Health Board
Alessandro Pileri
Associated Professor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Monika Klimkowska
Karolinska University Hospital
John Radford
The University of Manchester
David Teachey
Professor
Children's Hospital of Philadelphia
Antonia Rotolo
Imperial College London
Adam Snook
Professor
Thomas Jefferson University
Stephen Schuster
Professor, Clinician-Educator
Hospital of the University of Pennsylvania
Massimo Serra
Chief of the "Pharmacogenomics and Pharmacogenetics" Research Unit (Struttura Semplice)
IRCCS Istituto Ortopedico Rizzoli
Francine Foss
Yale University
Marco Gambarotti
IRCCS Istituto Ortopedico Rizzoli
Elisa Carretta
IRCCS Istituto Ortopedico Rizzoli
Marco Ruella
PI
University of Pennsylvania
FRANCA FAGIOLI
Professore Ordinario di Pediatria
Università degli Studi di Torino
Giorgio Frega
Istituto Ortopedico Rizzoli
Make your next move.
Prepare your application
Review drafts before you send them.